{
  "subtypes": {
    "Luminal A/B": {
      "description": "Hormone receptor positive (ER+/PR+), HER2 negative breast cancer",
      "therapy_levels": {
        "1": {
          "name": "Low Intensity Therapy",
          "description": "Conservative approach for low-risk disease",
          "recommendations": [
            {
              "therapy": "Endocrine therapy alone",
              "details": "Tamoxifen (premenopausal) or Aromatase Inhibitor (postmenopausal)",
              "duration": "5-10 years"
            },
            {
              "therapy": "Consider genomic testing",
              "details": "Oncotype DX or MammaPrint to assess recurrence risk",
              "indication": "For determining chemotherapy benefit"
            },
            {
              "therapy": "Omit chemotherapy",
              "details": "Low risk of recurrence based on clinical and genomic features",
              "evidence_level": "Level 1A"
            }
          ],
          "follow_up": "Every 6 months for 5 years",
          "indications": [
            "Small tumor size (≤2 cm)",
            "Low grade (Grade 1)",
            "Low Ki-67 (<10%)",
            "Low genomic risk score",
            "Older age (>70 years)"
          ]
        },
        "2": {
          "name": "Standard Therapy",
          "description": "Balanced approach for intermediate-risk disease",
          "recommendations": [
            {
              "therapy": "Endocrine therapy",
              "details": "Tamoxifen or Aromatase Inhibitor",
              "duration": "5-10 years"
            },
            {
              "therapy": "Consider chemotherapy",
              "details": "Based on higher recurrence risk",
              "regimen": "TC (Docetaxel/Cyclophosphamide) or AC-T (Anthracycline/Cyclophosphamide followed by Taxane)"
            },
            {
              "therapy": "Consider CDK4/6 inhibitor",
              "details": "Palbociclib, Ribociclib, or Abemaciclib",
              "indication": "For metastatic or high-risk early-stage disease"
            }
          ],
          "follow_up": "Every 4-6 months for 5 years",
          "indications": [
            "Intermediate tumor size (2-5 cm)",
            "Intermediate grade (Grade 2)",
            "Intermediate Ki-67 (10-20%)",
            "Intermediate genomic risk score",
            "1-3 positive lymph nodes"
          ]
        },
        "3": {
          "name": "Intensified Therapy",
          "description": "More aggressive approach for high-risk disease",
          "recommendations": [
            {
              "therapy": "Chemotherapy followed by endocrine therapy",
              "details": "Anthracycline/taxane-based regimen",
              "duration": "Chemotherapy: 4-6 months, Endocrine therapy: 5-10 years"
            },
            {
              "therapy": "CDK4/6 inhibitor + endocrine therapy",
              "details": "For metastatic disease or high-risk early-stage disease",
              "evidence_level": "Level 1A for metastatic, Level 2A for early-stage"
            },
            {
              "therapy": "Consider clinical trial",
              "details": "For novel therapies",
              "indication": "High-risk disease features"
            }
          ],
          "follow_up": "Every 3 months for 2 years, then every 6 months for 3 years",
          "indications": [
            "Large tumor size (>5 cm)",
            "High grade (Grade 3)",
            "High Ki-67 (>20%)",
            "High genomic risk score",
            "≥4 positive lymph nodes"
          ]
        },
        "4": {
          "name": "Maximum Intensity Therapy",
          "description": "Most aggressive approach for very high-risk disease",
          "recommendations": [
            {
              "therapy": "Dose-dense chemotherapy",
              "details": "Followed by extended adjuvant endocrine therapy",
              "regimen": "Dose-dense AC-T with growth factor support"
            },
            {
              "therapy": "Consider additional targeted therapy",
              "details": "Based on specific genomic alterations",
              "examples": "PI3K inhibitors for PIK3CA mutations, mTOR inhibitors"
            },
            {
              "therapy": "Clinical trial enrollment",
              "details": "For high-risk disease",
              "indication": "Very high-risk features or multiple recurrences"
            }
          ],
          "follow_up": "Every 2-3 months for 2 years, then every 3-4 months for 3 years",
          "indications": [
            "Inflammatory breast cancer",
            "Extensive lymph node involvement",
            "Young age with high-risk features",
            "High genomic risk score with multiple high-risk genomic alterations",
            "Rapid progression or recurrence after standard therapy"
          ]
        }
      },
      "biomarker_therapies": [
        {
          "biomarker": "PIK3CA_mutation",
          "therapy": "PI3K inhibitor (Alpelisib)",
          "indication": "Metastatic HR+/HER2- breast cancer with PIK3CA mutation",
          "evidence_level": "Level 1A"
        },
        {
          "biomarker": "ESR1_mutation",
          "therapy": "Fulvestrant",
          "indication": "Metastatic disease with ESR1 mutation after AI failure",
          "evidence_level": "Level 2A"
        }
      ]
    },
    "Luminal HER2+": {
      "description": "Hormone receptor positive (ER+/PR+), HER2 positive breast cancer",
      "therapy_levels": {
        "1": {
          "name": "Low Intensity Therapy",
          "description": "Conservative approach for low-risk disease",
          "recommendations": [
            {
              "therapy": "Endocrine therapy",
              "details": "Tamoxifen or Aromatase Inhibitor",
              "duration": "5-10 years"
            },
            {
              "therapy": "HER2-targeted therapy",
              "details": "Single-agent trastuzumab",
              "duration": "1 year"
            }
          ],
          "follow_up": "Every 3-4 months for 2 years, then every 6 months for 3 years",
          "indications": [
            "Very small tumor size (≤1 cm)",
            "Node-negative",
            "Low grade",
            "Elderly or frail patients"
          ]
        },
        "2": {
          "name": "Standard Therapy",
          "description": "Balanced approach for intermediate-risk disease",
          "recommendations": [
            {
              "therapy": "HER2-targeted therapy",
              "details": "Trastuzumab",
              "duration": "1 year"
            },
            {
              "therapy": "Endocrine therapy",
              "details": "Tamoxifen or Aromatase Inhibitor",
              "duration": "5-10 years"
            },
            {
              "therapy": "Consider low-intensity chemotherapy",
              "details": "Taxane-based",
              "regimen": "Weekly paclitaxel + trastuzumab"
            }
          ],
          "follow_up": "Every 3 months for 2 years, then every 4-6 months for 3 years",
          "indications": [
            "Tumor size 1-2 cm",
            "0-1 positive lymph nodes",
            "Intermediate grade"
          ]
        },
        "3": {
          "name": "Intensified Therapy",
          "description": "More aggressive approach for high-risk disease",
          "recommendations": [
            {
              "therapy": "Chemotherapy + dual HER2 blockade",
              "details": "Taxane + Trastuzumab + Pertuzumab",
              "duration": "Chemotherapy: 4-6 months, HER2 therapy: 1 year"
            },
            {
              "therapy": "Followed by endocrine therapy",
              "details": "Tamoxifen or Aromatase Inhibitor",
              "duration": "5-10 years"
            },
            {
              "therapy": "Extended HER2-targeted therapy",
              "details": "Complete one year of trastuzumab",
              "evidence_level": "Level 1A"
            }
          ],
          "follow_up": "Every 3 months for 2 years, then every 4 months for 3 years",
          "indications": [
            "Tumor size 2-5 cm",
            "2-3 positive lymph nodes",
            "High grade"
          ]
        },
        "4": {
          "name": "Maximum Intensity Therapy",
          "description": "Most aggressive approach for very high-risk disease",
          "recommendations": [
            {
              "therapy": "Neoadjuvant dual HER2 blockade + chemotherapy",
              "details": "Trastuzumab + Pertuzumab + Anthracycline/Taxane",
              "duration": "4-6 months neoadjuvant, complete 1 year HER2 therapy"
            },
            {
              "therapy": "Adjuvant T-DM1",
              "details": "For residual disease after neoadjuvant therapy",
              "duration": "14 cycles"
            },
            {
              "therapy": "Extended adjuvant therapy",
              "details": "Neratinib after trastuzumab + endocrine therapy",
              "duration": "1 year of neratinib"
            }
          ],
          "follow_up": "Every 2 months for 2 years, then every 3 months for 3 years",
          "indications": [
            "Tumor size >5 cm",
            "≥4 positive lymph nodes",
            "Inflammatory breast cancer",
            "Young age with high-risk features"
          ]
        }
      },
      "biomarker_therapies": [
        {
          "biomarker": "ERBB2_amplification",
          "therapy": "HER2-targeted therapy (Trastuzumab + Pertuzumab)",
          "indication": "Standard for all HER2+ breast cancers",
          "evidence_level": "Level 1A"
        }
      ]
    },
    "HER2 Enriched": {
      "description": "Hormone receptor negative (ER-/PR-), HER2 positive breast cancer",
      "therapy_levels": {
        "1": {
          "name": "Low Intensity Therapy",
          "description": "Conservative approach for low-risk disease",
          "recommendations": [
            {
              "therapy": "HER2-targeted therapy",
              "details": "Single-agent trastuzumab",
              "duration": "1 year"
            },
            {
              "therapy": "Low-intensity chemotherapy",
              "details": "Weekly paclitaxel",
              "duration": "12 weeks"
            }
          ],
          "follow_up": "Every 3 months for 2 years, then every 4 months for 3 years",
          "indications": [
            "Very small tumor size (≤1 cm)",
            "Node-negative",
            "Elderly or frail patients"
          ]
        },
        "2": {
          "name": "Standard Therapy",
          "description": "Balanced approach for intermediate-risk disease",
          "recommendations": [
            {
              "therapy": "HER2-targeted therapy",
              "details": "Trastuzumab",
              "duration": "1 year"
            },
            {
              "therapy": "Chemotherapy",
              "details": "Taxane-based",
              "regimen": "Weekly paclitaxel + trastuzumab or TCHP (Taxotere, Carboplatin, Herceptin, Perjeta)"
            },
            {
              "therapy": "Consider dual HER2 blockade",
              "details": "Add pertuzumab for higher risk",
              "evidence_level": "Level 1A"
            }
          ],
          "follow_up": "Every 3 months for 2 years, then every 4 months for 3 years",
          "indications": [
            "Tumor size 1-2 cm",
            "0-1 positive lymph nodes",
            "Intermediate grade"
          ]
        },
        "3": {
          "name": "Intensified Therapy",
          "description": "More aggressive approach for high-risk disease",
          "recommendations": [
            {
              "therapy": "Dual HER2 blockade",
              "details": "Trastuzumab + Pertuzumab",
              "duration": "1 year"
            },
            {
              "therapy": "Chemotherapy",
              "details": "Anthracycline/taxane-based regimen",
              "regimen": "AC-THP (Doxorubicin, Cyclophosphamide, followed by Taxol, Herceptin, Perjeta)"
            },
            {
              "therapy": "Consider neratinib",
              "details": "Extended adjuvant therapy after trastuzumab",
              "duration": "1 year"
            }
          ],
          "follow_up": "Every 2 months for 2 years, then every 3 months for 3 years",
          "indications": [
            "Tumor size 2-5 cm",
            "2-3 positive lymph nodes",
            "High grade"
          ]
        },
        "4": {
          "name": "Maximum Intensity Therapy",
          "description": "Most aggressive approach for very high-risk disease",
          "recommendations": [
            {
              "therapy": "Neoadjuvant dual HER2 blockade + chemotherapy",
              "details": "Trastuzumab + Pertuzumab + Anthracycline/Taxane",
              "duration": "4-6 months neoadjuvant, complete 1 year HER2 therapy"
            },
            {
              "therapy": "Adjuvant T-DM1",
              "details": "For residual disease after neoadjuvant therapy",
              "duration": "14 cycles"
            },
            {
              "therapy": "Clinical trial",
              "details": "Novel HER2-targeted approaches",
              "examples": "HER2-targeted ADCs, novel TKIs, immunotherapy combinations"
            }
          ],
          "follow_up": "Every 2 months for 2 years, then every 3 months for 3 years",
          "indications": [
            "Tumor size >5 cm",
            "≥4 positive lymph nodes",
            "Inflammatory breast cancer",
            "Young age with high-risk features"
          ]
        }
      },
      "biomarker_therapies": [
        {
          "biomarker": "ERBB2_amplification",
          "therapy": "HER2-targeted therapy (Trastuzumab + Pertuzumab)",
          "indication": "Standard for all HER2+ breast cancers",
          "evidence_level": "Level 1A"
        }
      ]
    },
    "Triple Negative": {
      "description": "Hormone receptor negative (ER-/PR-), HER2 negative breast cancer",
      "therapy_levels": {
        "1": {
          "name": "Low Intensity Therapy",
          "description": "Conservative approach for low-risk disease",
          "recommendations": [
            {
              "therapy": "Consider chemotherapy",
              "details": "TC regimen (docetaxel/cyclophosphamide)",
              "duration": "4 cycles"
            },
            {
              "therapy": "Observation",
              "details": "For very small, node-negative tumors",
              "indication": "Tumor size ≤0.5 cm, node-negative"
            }
          ],
          "follow_up": "Every 3 months for 2 years, then every 4 months for 3 years",
          "indications": [
            "Very small tumor size (≤0.5 cm)",
            "Node-negative",
            "Elderly or frail patients"
          ]
        },
        "2": {
          "name": "Standard Therapy",
          "description": "Balanced approach for intermediate-risk disease",
          "recommendations": [
            {
              "therapy": "Adjuvant chemotherapy",
              "details": "TC or AC-T regimen",
              "duration": "4-8 cycles depending on regimen"
            },
            {
              "therapy": "Consider platinum agent",
              "details": "Especially for BRCA-mutated tumors",
              "regimen": "Add carboplatin to standard regimen"
            },
            {
              "therapy": "Follow-up every 3-4 months",
              "details": "For early detection of recurrence",
              "duration": "At least 5 years"
            }
          ],
          "follow_up": "Every 3 months for 2 years, then every 4 months for 3 years",
          "indications": [
            "Tumor size 0.5-2 cm",
            "0-1 positive lymph nodes",
            "Intermediate grade"
          ]
        },
        "3": {
          "name": "Intensified Therapy",
          "description": "More aggressive approach for high-risk disease",
          "recommendations": [
            {
              "therapy": "Dose-dense chemotherapy",
              "details": "AC-T with growth factor support",
              "duration": "8 cycles total"
            },
            {
              "therapy": "Consider platinum agent",
              "details": "Carboplatin",
              "evidence_level": "Level 1B"
            },
            {
              "therapy": "Consider neoadjuvant approach",
              "details": "To assess treatment response",
              "indication": "Tumors >2cm or node-positive"
            },
            {
              "therapy": "Consider immunotherapy",
              "details": "For PD-L1 positive disease",
              "agent": "Pembrolizumab"
            }
          ],
          "follow_up": "Every 2 months for 2 years, then every 3 months for 3 years",
          "indications": [
            "Tumor size 2-5 cm",
            "2-3 positive lymph nodes",
            "High grade"
          ]
        },
        "4": {
          "name": "Maximum Intensity Therapy",
          "description": "Most aggressive approach for very high-risk disease",
          "recommendations": [
            {
              "therapy": "Neoadjuvant chemotherapy",
              "details": "Dose-dense AC-T + platinum",
              "duration": "6-8 cycles"
            },
            {
              "therapy": "Consider immunotherapy",
              "details": "Pembrolizumab for high-risk TNBC",
              "duration": "Up to 1 year"
            },
            {
              "therapy": "Clinical trial",
              "details": "Novel approaches for TNBC",
              "examples": "ADCs, immunotherapy combinations, PARP inhibitors"
            },
            {
              "therapy": "Consider PARP inhibitors",
              "details": "For BRCA-mutated tumors",
              "agent": "Olaparib or Talazoparib"
            }
          ],
          "follow_up": "Every 2 months for 2 years, then every 3 months for 3 years",
          "indications": [
            "Tumor size >5 cm",
            "≥4 positive lymph nodes",
            "Inflammatory breast cancer",
            "Young age with high-risk features"
          ]
        }
      },
      "biomarker_therapies": [
        {
          "biomarker": "BRCA1_mutation",
          "therapy": "PARP inhibitor (Olaparib, Talazoparib)",
          "indication": "BRCA-mutated metastatic TNBC",
          "evidence_level": "Level 1A"
        },
        {
          "biomarker": "BRCA2_mutation",
          "therapy": "PARP inhibitor (Olaparib, Talazoparib)",
          "indication": "BRCA-mutated metastatic TNBC",
          "evidence_level": "Level 1A"
        },
        {
          "biomarker": "PD-L1_positive",
          "therapy": "Pembrolizumab + chemotherapy",
          "indication": "PD-L1+ metastatic TNBC",
          "evidence_level": "Level 1A"
        }
      ]
    }
  },
  "special_biomarkers": {
    "TP53_mutation": {
      "clinical_significance": "Associated with more aggressive disease and poorer prognosis",
      "therapy_impact": "May suggest need for more intensive therapy",
      "monitoring": "Closer follow-up recommended"
    },
    "PIK3CA_mutation": {
      "clinical_significance": "Common in ER+ breast cancer, associated with resistance to endocrine therapy",
      "therapy_options": [
        {
          "name": "Alpelisib + Fulvestrant",
          "indication": "HR+/HER2- metastatic breast cancer with PIK3CA mutation",
          "evidence_level": "Level 1A"
        }
      ]
    },
    "BRCA1_mutation": {
      "clinical_significance": "Hereditary cancer risk, associated with TNBC phenotype",
      "therapy_options": [
        {
          "name": "PARP inhibitors",
          "agents": ["Olaparib", "Talazoparib"],
          "indication": "Metastatic breast cancer with germline BRCA mutations",
          "evidence_level": "Level 1A"
        },
        {
          "name": "Platinum chemotherapy",
          "indication": "Enhanced sensitivity in BRCA-mutated tumors",
          "evidence_level": "Level 2A"
        }
      ],
      "additional_recommendations": "Consider genetic counseling, family testing"
    },
    "BRCA2_mutation": {
      "clinical_significance": "Hereditary cancer risk, associated with luminal phenotype",
      "therapy_options": [
        {
          "name": "PARP inhibitors",
          "agents": ["Olaparib", "Talazoparib"],
          "indication": "Metastatic breast cancer with germline BRCA mutations",
          "evidence_level": "Level 1A"
        }
      ],
      "additional_recommendations": "Consider genetic counseling, family testing"
    },
    "ESR1_mutation": {
      "clinical_significance": "Associated with resistance to aromatase inhibitors",
      "therapy_options": [
        {
          "name": "Fulvestrant",
          "indication": "More effective than AIs in ESR1-mutated tumors",
          "evidence_level": "Level 2A"
        }
      ]
    },
    "ERBB2_amplification": {
      "clinical_significance": "Defines HER2+ breast cancer subtype",
      "therapy_options": [
        {
          "name": "Trastuzumab + Pertuzumab",
          "indication": "Standard therapy for HER2+ breast cancer",
          "evidence_level": "Level 1A"
        },
        {
          "name": "T-DM1",
          "indication": "Second-line therapy after trastuzumab failure",
          "evidence_level": "Level 1A"
        },
        {
          "name": "Tucatinib + Trastuzumab + Capecitabine",
          "indication": "HER2+ breast cancer with brain metastases",
          "evidence_level": "Level 1A"
        }
      ]
    },
    "MYC_amplification": {
      "clinical_significance": "Associated with more aggressive disease and poorer prognosis",
      "therapy_impact": "May suggest need for more intensive therapy"
    },
    "CCND1_amplification": {
      "clinical_significance": "Common in ER+ breast cancer, may predict CDK4/6 inhibitor response",
      "therapy_options": [
        {
          "name": "CDK4/6 inhibitors",
          "agents": ["Palbociclib", "Ribociclib", "Abemaciclib"],
          "indication": "HR+/HER2- breast cancer",
          "evidence_level": "Level 1A"
        }
      ]
    },
    "PTEN_loss": {
      "clinical_significance": "Associated with resistance to HER2-targeted therapy and PI3K pathway activation",
      "therapy_impact": "May predict response to PI3K/AKT/mTOR inhibitors"
    },
    "RB1_loss": {
      "clinical_significance": "May predict resistance to CDK4/6 inhibitors",
      "therapy_impact": "Consider alternative approaches in HR+ disease"
    }
  },
  "therapy_levels": {
    "1": {
      "name": "Low Intensity Therapy",
      "description": "Conservative approach for low-risk disease or patients with comorbidities",
      "general_indications": [
        "Small tumors (≤1 cm)",
        "Node-negative disease",
        "Low-grade histology",
        "Low genomic risk scores",
        "Elderly or frail patients",
        "Significant comorbidities"
      ],
      "follow_up": "Every 3-6 months for 5 years",
      "monitoring": "Annual mammogram, consider breast MRI for high-risk patients"
    },
    "2": {
      "name": "Standard Therapy",
      "description": "Balanced approach for most patients with average risk disease",
      "general_indications": [
        "Intermediate tumor size (1-3 cm)",
        "0-1 positive lymph nodes",
        "Intermediate-grade histology",
        "Intermediate genomic risk scores"
      ],
      "follow_up": "Every 3-4 months for 2 years, then every 6 months for 3 years",
      "monitoring": "Annual mammogram, consider breast MRI for dense breasts"
    },
    "3": {
      "name": "Intensified Therapy",
      "description": "More aggressive approach for high-risk disease",
      "general_indications": [
        "Large tumors (3-5 cm)",
        "2-3 positive lymph nodes",
        "High-grade histology",
        "High genomic risk scores",
        "Young age (<40 years) with other risk factors"
      ],
      "follow_up": "Every 3 months for 2 years, then every 4 months for 3 years",
      "monitoring": "Annual mammogram and breast MRI, consider more frequent imaging"
    },
    "4": {
      "name": "Maximum Intensity Therapy",
      "description": "Most aggressive approach for very high-risk disease",
      "general_indications": [
        "Very large tumors (>5 cm)",
        "≥4 positive lymph nodes",
        "Inflammatory breast cancer",
        "Multiple high-risk genomic alterations",
        "Young age with high-risk features"
      ],
      "follow_up": "Every 2-3 months for 2 years, then every 3-4 months for 3 years",
      "monitoring": "Mammogram and breast MRI every 6 months, consider CT/PET scans"
    }
  }
}